QYResearch: In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD

Page 1

QYResearch focus on Market Survey and Research

qyresearchglobal.com


QYResearch

Contact Beijing Hengzhou Bozhi International Information Consulting Web: qyresearchglobal.com | qyresearcheurope.com |

qyresearch.com | qyresearch.com/english | qyresearchjapan.com TEL:+86-13660489419, Office:+86-2086655165 Media: press@qyresearch.com

Marketing: sales@qyresearch.com

Facebook:@QYResearchOfficial, Twitter: @QYResearch_ Wechat: QYResearch, Weibo: 恒州博智

qyresearchglobal.com


QYResearch Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.

qyresearchglobal.com


QYResearch In the last several years, global market of bacterial vaginosis drug developed smoothly, with an average growth rate of 3.01%. In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD. The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

According to QYResearch, Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD. USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016. USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

qyresearchglobal.com


QYResearch

Full Report Link: http://www.qyresearchglobal.com/goods-1027455.html

qyresearchglobal.com


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.